Diversified Consumer Services
Company Overview of Baylor College of Medicine
Baylor College of Medicine is an education, research, and patient care institution that comprises Neurology, Neuroscience, Neurosurgery, Obstetrics and Gynecology, Ophthalmology, Orthopedic Surgery, Otorhinolaryngology & Communicative Sciences, Pathology, Pediatrics, Pharmacology, and Cardiovascular Sciences, Dermatology, and Developmental Biology departments. It also consists of Center for Cell and Gene Therapy, Center for Medical Ethics and Health Policy, Children's Nutrition and Research Center, Huffington Center on Aging, and Winters Center. Baylor College of Medicine was founded in 1900 and is based in Houston, Texas. It has endowment assets worth $ 1.44 billion.
One Baylor Plaza
Mail Stop 160
Houston, TX 77030
Founded in 1900
Key Executives for Baylor College of Medicine
Chief Executive Officer and President
Chairman of the Department of Neurology
Executive Vice President and Executive Dean
Senior Vice President and Dean of Research
Compensation as of Fiscal Year 2015.
Baylor College of Medicine Key Developments
DNAnexus and the Human Genome Sequencing Center at Baylor College of Medicine Collaborate to Develop and Globally Deploy Comprehensive Clinical Whole Genome Analysis Platform
Jun 22 15
DNAnexus announced a collaboration with The Human Genome Sequencing Center at Baylor College of Medicine, to co-develop HgV, the next generation of the HGSC’s Mercury solutions pipeline. HgV is a comprehensive framework for large-scale high-throughput whole genome sequence analysis in the settings of precision medicine research and clinical applications. The HGSC’s Mercury pipeline is the core data-processing and variant-calling tool for the cloud-based genome analysis projects, including the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the Alzheimer’s Disease Sequencing Project, and the Baylor-Hopkins Center for Mendelian Genomics. This pipeline is used in clinical studies to identify mutations from genomic data to determine the significance of these mutations as a cause of serious disease. HGSC continues to be at the forefront of technical innovation and bioinformatics development. Partnering with DNAnexus, HGSC’s team of bioinformatics experts have expanded their capability for rapid development and deployment of HgV to the broader research community via the leading cloud-based bioinformatics platform – DNAnexus. HgV is optimized for Illumina X Ten levels of throughput and whole-genome data processing, analytics, and collaboration. Drawing on extensive R&D of high-quality personal genomes and large disease cohorts, this platform will provide an improved alternative to existing methods and multiple protocols for comprehensive whole genomes: 'Parliamentary' approach to the discovery and evaluation of large, structural variants inaccessible to targeted genome sequencing, multi-source functional whole-genome annotation of both protein-coding and non-coding regions, aggregation of annotation, phenotype, and variant information in a NoSQL-based extensible and scalable data warehouse, integration of heterogeneous library protocols and sequencing platforms, including long-read sequencing and SNP arrays, project-specific 'Afterburners', such as variant prioritization for Mendelian Diseases, pedigree sample sets, de novo mutation analysis in trios, cancer, and case/control studies. As the cost of whole genome sequencing (WGS) continues to decline and the quality increases, its use for novel discovery and to identify genetic disorders in the clinic is becoming routine. Although most identified disease-causing variants fall within the exome, WGS can identify non-coding variants and large, structural variants that may contribute to complex and common diseases, especially in cases that have proven elusive to exome analysis. DNAnexus sits at the forefront of cloud-based data security, compliance and controlled access. By co-developing with DNAnexus, the HGSC can deploy HgV into an investigative environment while leveraging extensive research experience. These efforts include establishing an exceptionally high-quality personal genome for testing, benchmarking and validating protocols, methods and tools. The raw sequence data from multiple platforms have been subject to deep variant calling, trio analysis, whole genome assembly, long-read structural variant analysis, and Mendelian prioritization, generating high-quality variants that can be used for future tool validation. HgV development includes specific emphasis on trackability, versioning and reproducibility to enable seamless transition into a CAP/CLIA environment. HgV is an open-source and fully configurable platform that will be equipped with pre-configured DNAnexus workflows for various use cases, including optimized speed, sensitivity, and accuracy. Designed with the Illumina HiSeq X Ten platform in mind, it provides a secure and scalable environment for single samples and multi-sample projects, allowing users to focus on interpreting their data rather than local IT infrastructure and data logistics. Through DNAnexus, this Data Commons model serves as a global framework for developers and downstream users to implement new methods, share data, provide feedback, and identify new collaborations.
Baylor College of Medicine Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 08:10 AM
Feb 28 15
Baylor College of Medicine Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 08:10 AM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: Malcolm Brenner, Founding Director, Center for Cell and Gene Therapy.
Baylor College of Medicine and Miraca Holdings Inc. Finalize Joint Venture on Clinical Genetic Testing
Feb 2 15
Baylor College of Medicine and Miraca Holdings Inc. finalized a joint venture in which the College will share ownership and governance of its clinical genetics diagnostic laboratories with the Japan-based international healthcare company that has a focus on clinical diagnostics and laboratory tests. The name of the new entity is Baylor Miraca Genetics Laboratories. Baylor Miraca Genetics will be built on Baylor's existing Medical Genetics Laboratories, which engages in clinical laboratory genetic testing. Baylor and Miraca agreed on the terms of the joint venture on Oct. 31, with Dr. Paul Klotman, president, CEO and executive dean of Baylor, and Dr. Hiromasa Suzuki, president and CEO of Miraca, signing the documents in Houston. In the weeks that followed, work was completed on the governmental, business and scientific regulatory approvals needed for closing. The jointly-owned clinical diagnostic venture will be headquartered in Houston, initially in space in the McGovern Building on the McGovern Campus in the Texas Medical Center, the same location as under Baylor.
Similar Private Companies By Industry
Recent Private Companies Transactions